1. Generics Bulletin
  2. >>Business
  3. >>Strategy

Viatris Pushes Back ‘Roadmap’ Reveal

Investor Event To Unveil Detailed Strategy Had Been Planned For 7 January

 
• By Dave Wallace

Viatris has delayed the big reveal of details of its two-phase strategic roadmap that had been due to take place at an investor event planned for early January.

January February 2022 Calendar
The postponed investor event could be as late as 28 February 2022 • Source: Alamy

Investors and industry analysts will now have to wait a little longer to learn details of Viatris’ long-term “strategic roadmap,” after the company announced that an investor event scheduled for 7 January 2022 had been delayed to “no later than 28 February when the company expects to report its fourth quarter 2021 results.” 

Viatris had in November unveiled plans for the “virtual investor event” in January, which it said would include detailed financial...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Room For Improvement? EU Industry Prepares Feedback For SPC Manufacturing Waiver Review

 
• By Dave Wallace

As the European Commission prepares a formal evaluation of the SPC manufacturing waiver, the generics and biosimilars industry is getting ready to provide detailed feedback on what works – and what doesn’t. At Medicines for Europe’s legal affairs conference, delegates heard the latest updates.

Wockhardt Pivots To Biosimilar Insulins Focus As It Confirms US Generics Exit

 
• By Dean Rudge

Wockhardt is exiting the US generics market through voluntary liquidation of its loss-making US subsidiaries to double down on innovation and focus on antibiotics and biosimilar insulins.

Biocon’s Denosumab Biosimilar Approved In The UK As Competition Grows In Europe

 
• By Urtė Fultinavičiūtė

Denosumab biosimilar ranks are filling up in Europe as approvals flood in. Yet, little is known about the launch dates.